Progress Toward an Ideal Sleeping Pill - 18/03/25
Doi : 10.1016/j.amjmed.2024.11.019
Reynold Spector, MD ⁎ 
Executive Vice President, Merck–retired 1999, Clinical Professor of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ
⁎Requests for reprints should be addressed to Reynold Spector, MD, 551 North Road, #1212, Westfield, MA 01085.551 North Road, #1212WestfieldMA01085
Abstract |
Thirty percent of Americans report insomnia. After eliminating obvious causes, the best therapy for insomnia is cognitive behavioral therapy, but this is not widely available. However, all the known oral sleeping aides are generally unsatisfactory. Recently, a new class of safe, nonaddicting, mechanism-based hypocretin blockers have been developed. Herein we review the information not only for insomnia but also for narcolepsy.
Le texte complet de cet article est disponible en PDF.Keywords : Insomnia, Hypocretinss, Narcloepsy, Orexin
| Funding: This review had no funding. |
|
| Conflicts of Interest: None. |
|
| Authorship: The sole author is responsible for all content: RS: Conceptualization, Investigation, Writing – original draft, review, and editing. |
© 2024
Elsevier Inc. Tous droits réservés.
Vol 138 - N° 4
P. 608-611 - avril 2025 Retour au numéro
Article précédent
- Creating New Proteins for Medical Therapeutics
- Edward J. Goetzl
- A Service-Oriented Pre-Visit Planning Model to Improve Quality Metrics in Primary Care
- Molly F. MacIsaac, Jennifer Crema, Jennifer Brock, Amy Musnik, Linda Pollack, Gianna Crema, Dara Brener
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?